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 Abstract 
 
Background. Chronic obstructive pulmonary disease (COPD) is a respiratory system 
disease that causes high morbidity and mortality in the world. 
Exposure to oxidant substances from smoking and air pollution on the lungs will lead to 
lung inflammation and worsening of COPD conditions. Therefore we need an 
antioxidant agent that can inhibit oxidative stress in order to obtain improved health 
status in COPD patients.Objectives. To analyze the comparison between the health 
status of COPD patients who get regular pharmacotherapy and COPD patients who 
received additional erdosteine in their treatment. Methods. Randomized-double blind 
study. The study subjects were divided into two randomized groups, regular 
pharmacotherapy group (control) and groups of regular pharmacotherapy plus 
erdosteine (test). Observations made during the 10 days, the parameter used is the score 
of Clinical COPD Questionnaire. Outcomes. In the control group, after 10 days, the 
values obtained between pre-test and post-test differ significantly in symptom score (p = 
0.000; CI 95%), functional score (p = 0.001; CI 95%), mental score (p = 0.001; CI 95%), 
and total score (p = 0.000; CI 95%). Likewise, the value in the test group, symptom 
score (p = 0.000; CI 95%), functional score (p = 0.002; CI 95%), mental score (p = 
0.000; CI 95%), and total score (p = 0.000; CI 95%). However, the improvements that 
analyzed with delta scores between pre-test and post test showed a better improvement 
in the test group symptom score (p = 0.040; CI 95%), mental score (p = 0.023; CI 95%), 
and total score (p = 0.022; CI 95%). Meanwhile, the delta functional score between the 
two groups was not significant (p = 0.835; CI 95%). Conclusion. Overall, regular 
pharmacotherapy or with additional erdosteine can provide significant improvements in 
COPD patients, but the value of improvements is greater in patients who get an 
additional erdosteine. 
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